23095-16-1

Upstream product

• 2398-37-0 3-methoxyphenyl bromide 

Downstream Products

• 153624-70-5 N-(3,4-dimethyl-5-isoxazolyl)-2-bromo-4-methoxybenzenesulfonamide 
• 1038988-09-8 1-(2-bromo-4-methoxybenzenesulfonyl)-4-(4-methylpiperazin-1-ylmethyl)-1H-indole 
• 23095-17-2 2-Brom-4-methoxy-benzolsulfonsaeurehydrazid 
• 1301768-16-0 2-bromo-4-methoxy-N-(2-methylallyl)benzenesulfonamide 
• 1301768-03-5 tert-butyl N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(4R)-7-methoxy-4-methyl-1,1-dioxo-1,3,4,5-tetrahydro-2H-1λ6,2-benzothiazepin-2-yl]propyl}carbamate 
• 1309607-04-2 C₂₁H₂₈N₂O₄S 
• 1309607-08-6 C₂₁H₂₈N₂O₄S 
• 1301768-24-0 C₂₆H₃₆N₂O₆S 
• 1301768-04-6 tert-butyl N-{(1S,2R)-1-benzyl-2-hydroxy-3-[(4S)-7-methoxy-4-methyl-1,1-dioxo-1,3,4,5-tetrahydro-2H-1λ6,2-benzothiazepin-2-yl]propyl}carbamate 
• 153624-71-6 N-(3,4-dimethyl-5-isoxazolyl)-N-((methoxyethoxy)methyl)-2-bromo-4-methoxybenzenesulfonamide 

Relevant academic research and scientific papers

Ammonium formate-based one-pot reductive Heck reactions for the construction of cyclic sulfonamides

A modified method is reported for the conversion of unsaturated sulfonamides into their cyclic saturated counterparts. This method utilises a single palladium catalyst for an intramolecular Heck reaction and subsequent transfer hydrogenation, which is ach

PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS

The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors . Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.

Biphenylsulfonamide endothelin antagonists: Structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N-(3,4- dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide (BMS- 187308)

Substitution at the ortho position of N-(3,4-dimethyl-5-isoxazolyl) benzenesulfonamide led to the identification of the biphenylsulfonamides as a novel series of endothelin-A (ETA) selective antagonists. Appropriate substitutions on the pendant phenyl ring led to improved binding as well as functional activity. A hydrophobic group such as isobutyl or isopropoxyl was found to be optimal at the 4'-position. Introduction of an amino group at the 2'-position also led to improved analogues. Combination of the optimal 4'- isobutyl substituent with the 2'-amino function afforded an analogue (20, BMS-187308) with improved ET(A) binding affinity and functional activity. Compound 20 also has good oral activity in inhibiting the pressor effect caused by an ET-1 infusion in rats. Doses of 10 and 30 μmol/kg iv 20 attenuated the pressor responses due to the administration of exogenous ET-1 to conscious monkeys, indicating that the compound inhibits the in vivo activity of endothelin-1 in nonhuman primates.

PHENYL SULFONAMIDE ENDOTHELIN ANTAGONISTS

Compounds of the formula STR1 inhibit the activity of endothelin. The symbols are defined as follows: R 1, R 2 and R. sup.3 are each independently(a) hydrogen, except that R. sup.1 is other than hydrogen;(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z 1, Z 2 and Z. sup.3 ;(c) halo;(d) hydroxyl;(e) cyano; (f) nitro; (g)--C(O)H or--C(O)R 6 ;(h)--CO 2 H or--CO 2 R 6 ; (i)--SH,--S(O) n R 6,--S(O) m--OH,--S(O) m--OR 6,--O--S(O) m--R 6,--O--S(O) m OH or--O--S(O) m--OR. sup.6 ;(j)--Z. sup.4--NR 7 R 8 ; or (k)--Z 4--N(R 11--Z 5--NR 9 R 10 ; and the remaining symbols are as defined in the specification.